| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8221271 | International Journal of Radiation Oncology*Biology*Physics | 2013 | 8 Pages |
Abstract
Head-and-neck cancer patients tolerated everolimus at therapeutic doses (5 mg/day) given with weekly cisplatin and intensity modulated radiation therapy. The regimen merits further evaluation, especially among patients who are status post resection of HNSCCs that harbor mTORC1-mediated activation of eIF4E in histologically negative surgical margins.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Matthew G. MD, PhD, Nancy Y. MD, Eric MD, Alan L. MD, PhD, Shyam MD, Adriana PhD, Ronglai PhD, Susan BS, Donna BA, Ian MD, Snehal MD, Richard J. MD, Ashok MD, Jatin MD, Sofia MD, Nora MD, David G. MD,